Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NTRK1 | P04629 | 5/20 | 0.44 |
| ▸ | ALK | Q9UM73 | 4/20 | 0.44 |
| ▸ | JAK2 | O60674 | 4/20 | 0.42 |
| ▸ | JAK3 | P52333 | 3/20 | 0.42 |
| ▸ | JAK1 | P23458 | 2/20 | 0.42 |
| ▸ | FYN | P06241 | 4/20 | 0.41 |
| ▸ | MKNK1 | Q9BUB5 | 3/20 | 0.41 |
| ▸ | DYRK1A | Q13627 | 6/20 | 0.39 |
| ▸ | DYRK2 | Q92630 | 6/20 | 0.39 |
| ▸ | DYRK1B | Q9Y463 | 6/20 | 0.39 |
| ▸ | DYRK3 | O43781 | 5/20 | 0.39 |
| ▸ | CCNA2 | P20248 | 2/20 | 0.39 |
| ▸ | CDK2 | P24941 | 2/20 | 0.39 |
| ▸ | CDK5 | Q00535 | 2/20 | 0.39 |
| ▸ | CDK5R1 | Q15078 | 2/20 | 0.39 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.37 |
| ▸ | CDK9 | P50750 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9905667 | 1.00 | NTRK1 (0.44) | NTRK1ALKJAK2JAK3JAK1 | |
| SCHEMBL9903343 | 1.00 | NTRK1 (0.44) | NTRK1ALKJAK2JAK3JAK1 | |
| SCHEMBL9905682 | 0.88 | ALK (0.44) | NTRK1ALKFYNMKNK1DYRK1A | |
| SCHEMBL9902785 | 0.88 | ALK (0.44) | NTRK1ALKFYNMKNK1DYRK1A | |
| SCHEMBL9903474 | 0.88 | NTRK1 (0.46) | NTRK1ALKJAK2JAK3JAK1 | |
| SCHEMBL8513514 | 0.88 | ALK (0.44) | NTRK1ALKJAK2JAK3JAK1 | |
| SCHEMBL8513505 | 0.88 | ALK (0.44) | NTRK1ALKJAK2JAK3JAK1 | |
| SCHEMBL9903333 | 0.86 | NTRK1 (0.47) | NTRK1ALKJAK2JAK3JAK1 | |
| SCHEMBL9903335 | 0.86 | NTRK1 (0.47) | NTRK1ALKJAK2JAK3JAK1 | |
| SCHEMBL9905701 | 0.85 | ALK (0.44) | NTRK1ALKJAK2JAK3JAK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9133200-B2 | Imidazo[1,2-b]pyridazine and imidazo[4,5-b]pyridine derivatives as JAK inhibitors | ALMIRALL, S.A. (ES) | 2015-09-15 | — | — | US | claimed |
| US-20130309200-A1 | IMIDAZO [1,2-B] PYRIDAZINE AND IMIDAZO [4,5-B] PYRIDINE DERIVATIVES AS JAK INHIBITORS | ALMIRALL, S.A. (ES) | 2013-11-21 | — | — | US | claimed |
| EP-2463289-A1 | Imidazo[1,2-b]pyridazine derivatives as JAK inhibitors | Almirall, S.A. (ES) | 2012-06-13 | — | — | EP | claimed |
| US-9133200-B2 | Imidazo[1,2-b]pyridazine and imidazo[4,5-b]pyridine derivatives as JAK inhibitors | ALMIRALL, S.A. (ES) | 2015-09-15 | — | — | US | disclosed |
| US-20130309200-A1 | IMIDAZO [1,2-B] PYRIDAZINE AND IMIDAZO [4,5-B] PYRIDINE DERIVATIVES AS JAK INHIBITORS | ALMIRALL, S.A. (ES) | 2013-11-21 | — | — | US | disclosed |
| EP-2463289-A1 | Imidazo[1,2-b]pyridazine derivatives as JAK inhibitors | Almirall, S.A. (ES) | 2012-06-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130309200-A1 | IMIDAZO [1,2-B] PYRIDAZINE AND IMIDAZO [4,5-B] PYRIDINE DERIVATIVES AS JAK INHIBITORS | JAK1, JAK2, JAK3 | NTRK1 2216/4885ALK 282/4885JAK2 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.